CXCR2 and its ligand CXCL1 contribute to the resistance of chemotherapy in mammary tumor cells and the knockdown of CXCR2 enhances sensitivity to chemotherapy and inhibits tumor cell metastasis [50, 51]. This evidence concerns the gene CXCL1 and breast cancer.